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ABSTRACT Elevated plasma lipids, glucose, insulin, and fatty liver are among components of metabolic syndrome, a phe-
notypic pattern that typically precedes the development of Type 2 diabetes. Animal studies show that intake of anthocyanins
reduces hyperlipidemia, obesity, and atherosclerosis and that anthocyanin-rich extracts may exert these effects in association
with altered activity of tissue peroxisome proliferator-activated receptors (PPARs). However, studies are lacking to test this
correlation using physiologically relevant, whole food sources of anthocyanins. Tart cherries are a rich source of anthocyanins,
and whole cherry fruit intake may also affect hyperlipidemia and/or affect tissue PPARs. This hypothesis was tested in the
Dahl Salt-Sensitive rat having insulin resistance and hyperlipidemia. For 90 days, Dahl rats were pair-fed AIN-76a-based di-
ets supplemented with either 1% (wt:wt) freeze-dried whole tart cherry or with 0.85% additional carbohydrate to match
macronutrient and calorie provision. After 90 days, the cherry-enriched diet was associated with reduced fasting blood glu-
cose, hyperlipidemia, hyperinsulinemia, and reduced fatty liver. The cherry diet was also associated with significantly en-
hanced hepatic PPAR- mRNA, enhanced hepatic PPAR- target acyl-coenzyme A oxidase mRNA and activity, and in-
creased plasma antioxidant capacity. In conclusion, physiologically relevant tart cherry consumption reduced several phenotypic
risk factors that are associated with risk for metabolic syndrome and Type 2 diabetes. Tart cherries may represent a whole
food research model of the health effects of anthocyanin-rich foods and may possess nutraceutical value against risk factors
for metabolic syndrome and its clinical sequelae.
KEY WORDS: • anthocyanin • diabetes • diet
252
INTRODUCTION
HYPERLIPIDEMIA, hyperinsulinemia, and elevated fastingblood glucose are among several clinical parameters of
prediabetes or the “metabolic syndrome” and are positively
correlated with the incidence of Type 2 diabetes and cardio-
vascular disease. The American Heart Association estimates
that 25% of Americans display indices of metabolic syn-
drome, which can progress silently towards frank diabetes
and heart disease.1 Fruit and vegetable intake is inversely
correlated with morbidity and mortality. Furthermore, fruits
and vegetables contain non-nutritive phytochemicals that
may contribute to their health-promoting effects.
Anthocyanins are one of the major subclasses of phyto-
chemical flavonoids, and they are principally found in 
red-, blue-, and purple-pigmented fruits and vegetables. Sev-
eral studies have suggested that several botanical extracts,
including anthocyanin-rich extracts, modify lipid metabo-
lism in vitro and can reduce hyperlipidemia in vivo.2–7 While
reductionistic approaches to phytochemical research are
valuable for mechanistic studies, the results should be paired
with physiologically relevant, whole foods approaches to as-
sess biologic relevance.
Isolated anthocyanins and anthocyanin-rich extracts were
recently shown to modify the activity of peroxisome prolif-
erator-activated receptors (PPARs).8,9 PPAR is a transcrip-
tion factor that controls genes that modify blood lipoprotein
metabolism and tissue lipolysis. Depending on the targeted
PPAR isoform, PPAR agonists can alter blood lipids, alter
fat metabolism in tissues, and improve insulin resis-
tance.10–12 Pharmaceutical PPAR agonist drugs reduce
plasma cholesterol and triglycerides (PPAR- agonist drugs,
like fibrates) and improve insulin sensitivity (PPAR- ago-
nist drugs, like thiazolidinediones). While concentrated an-
thocyanin-rich extracts have recently demonstrated effects
on PPAR isoform expression, it is unknown if physiologi-
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cally relevant doses of anthocyanin-rich whole foods could
exert a nutraceutical effect on PPAR.
This gap in knowledge is addressed herein using daily
diet enrichment with whole tart cherry powder. Tart cher-
ries (Prunus cerasus) are a rich source of anthocyanins.13,14
Given the observed effects of anthocyanins on PPARs and
the effect of PPAR agonists on metabolic syndrome, we
tested the hypothesis that intake of tart cherry-supplemented
diet would modify indices of metabolic syndrome and mod-
ify PPARs in the Dahl-Salt Sensitive (Dahl-SS) rat model.
Dahl-SS animals develop hyperlipidemia and insulin resis-
tance in the absence of obesity.15–18 Dahl-SS rats display
both enhanced hepatic very low-density lipoprotein (VLDL)
production and reduced VLDL-triglyceride clearance via re-
duced lipoprotein lipase activity.16,17,19,20 Importantly,
Dahl-SS rat hyperlipidemia and insulin resistance are sig-
nificantly improved by PPAR agonist drugs.21–24
We tested the health effect of subchronic (90-day) diet
provision of whole tart cherry powder at 1% of the diet by
weight. We expect that cherry-enriched diets would decrease
plasma hyperlipidemia. Because the liver is the primary
source of lipogenesis in rodent models, we measured hepatic
lipid content as well as the levels of PPAR isoforms and of
PPAR-related transcripts involved in lipid balance. Acyl-
coenzyme A (CoA) oxidase (ACO) mRNA served as a
marker for hepatic PPAR- activation, while fatty acid syn-




Male Dahl-SS Rats (Rapp strain, 5 weeks old) were ac-
quired from Harlan (Indianapolis, IN) and were housed three
per cage. Rats were housed on 12-hour light:dark cycles. At
6 weeks of age, rats were randomized to two groups (n 
12 each): 1% cherry powder by weight or 0.85% additional
carbohydrate by weight (dextrose:fructose 1:1) to control for
the additional carbohydrate provided by the cherry powder.
The cherry product employed was a freeze-dried powder
from individually quick frozen (IQF) Montmorency tart
cherries, harvested in northern Michigan and prepared by
VanDrunen Farms (Momence, IL). Nutrient analysis (Table
1) was conducted by VanDrunen Farms and its subsidiary
Futureceuticals (Momence), and further anthocyanin analy-
sis was conducted by our group (Table 2) as described be-
low. Cherry powder or the dextrose:fructose mixture was in-
corporated into powdered AIN-76a diet (Research Diets,
New Brunswick, NJ). Diets were mixed weekly, vacuum-
sealed, and stored at 4°C. Rats were pair-fed 20 g of diet
per head per day, and water was provided ad libitum. This
protocol was approved by the University of Michigan’s Uni-
versity Committee on the Use and Care of Animals.
Product characterization: extraction and liquid
chromatography-mass spectrometry (LC-MS) 
analysis of tart cherry powder
IQF tart cherry powder (1 g) was extracted with 10 mL
of methanol/water/acetic acid (85:15:0.5 by volume) in a 15-
mL screw-cap tube and shaken overnight in the dark at 4°C.
The sample was vortex-mixed and then sonicated for 10
minutes at 25°C. After filtration (pore size, 0.45 m), the
extract was ready for LC-MS analysis. An Alliance 2695
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TABLE 1. PROFILES OF CHERRY-SUPPLEMENTED DIET (CHE) AND
CARBOYDRATE-SUPPLEMENTED CONTROL DIET (CON)
CHE CON
% of diet
Total protein 21.0 20.0
Total carbohydrate 65.4 65.4
Total fat 5.0 5.0
kcal/g of diet 3.9 3.9
g/kg diet
Casein 198 198








Fiber from cherry 0.9 0
Corn oil 49.5 49.6
Choline bitartrate 1.9 1.9
Cholesterol 0 0
AIN76a vitamin mix 10 10
AIN 76a mineral mix 35 35
Vitamin C 0.002 0
Vitamin A 441.4 IU 0




IU, International Units; RE, retinol equivalence.
TABLE 2. TART CHERRY POWDER PHYTOCHEMICAL













high-performance liquid chromatograph (Waters, Milford,
MA) was used to generate a binary gradient with 0.05% tri-
fluoroacetic acid in water as the aqueous solvent (A) and
0.05% trifluoroacetic acid in acetonitrile as the organic mod-
ifier (B). Chromatographic separation was achieved with a
Gemini 5-m C18 150-  2.00-mm (Phenomenex, Tor-
rance, CA) reverse-phase column held at 35°C using a flow
rate of 0.19 mL/minute. The column was initially equili-
brated to 8% B, increased to 18% B over 10 minutes, 28%
B over the next 8 minutes, 40% B in 1 minute, and 60% B
in 3 minutes, and then returned to initial conditions. The
sample chamber was cooled to 10°C, and the injection vol-
ume was 10 L. Effluent from the high-performance liquid
chromatography column was directed into the electrospray
ionization probe of a TSQ Quantum Ultra AM triple quadru-
pole mass spectrometer (ThermoFinnigan, San Jose, CA).
Positive ions were generated with the following parameters:
spray voltage, 3,000 V; sheath gas setting 40; auxiliary gas
setting 10; capillary temperature 250°C. Tube lens voltages
were optimized for each compound. Data were collected in
centroid mode. Single reaction monitoring was used for
mass analysis and quantification. Data analysis was per-
formed with Xcalibur™ quantitation software (version 1.4
SR1, ThermoFinnigan).
Biological sample collection
After 90 days of feeding, rats were fasted for 18 hours
and then sacrificed by decapitation, and trunk blood was col-
lected. Heart, kidneys, and liver were harvested, blotted, and
weighed. Whole blood was collected in 0.6-mL capacity
serum-separator tubes, allowed to clot at room temperature,
and spun at 5,000 g for 7 minutes at 4°C. Serum was
aliquoted and stored at 80°C until further analysis. Whole
blood was collected in a 7-mL EDTA-Vacutainer® (BD,
Franklin Lakes, NJ) and spun at 4°C at 1,500 g. Plasma was
then aliquoted and stored at 80°C until further analysis.
Serum and plasma analysis
Clinical chemistries were run on serum using the auto-
mated VetTest® Chemistry Analyzer (IDEXX Laboratories,
Westbrook, ME). Plasma insulin and 8-isoprostane were
measured by immunoassay (Cayman Chemical, Ann Arbor,
MI) according to the manufacturer’s instructions. Plasma an-
tioxidant capacity was measured by the total antioxidant ca-
pacity assay (TAS, Randox Laboratories, Crumlin, UK) ac-
cording to the manufacturer’s instructions, but with volumes
modified for high-throughput analysis using the microplate
method as we have conducted and described previously.25
Real-time polymerase chain reaction (PCR)
Hepatic total RNA was isolated from three animals per
group with Trizol reagent (Invitrogen, Carlsbad, CA) and
subsequently further purified using the ArrayGrade™ Total
RNA Isolation kit (SuperArray Bioscience, Frederick, MD),
following the manufacturer’s protocol. For real-time PCR,
3 g of hepatic total RNA from each rat was used to make
first-strand cDNA. Real-time PCR assays were performed
with 1 L of cDNA using RT2 Real-Time™ SYBR Green
master mix (SuperArray) in the ABI Prism 7700 (Ap-
plied Biosystems, Foster City, CA). The rat-specific PPAR
primer pairs were obtained from SuperArray (PPAR-,
catalog number PPR44459A; PPAR-, catalog number
PPR47599A; ACO, catalog number PPR48458A; FAS,
catalog number PPR44358E). The sequence of rat 18S
primers was forward 5-AGTCCCTGCCCTTTGTACACA-
3 and reverse 5-GATCCGAGGGCCTCACTAAAC-3.
Cycle threshold (Ct) was plotted as a standard curve for each
target. For each gene, we ran an amplification efficiency val-
idation experiment by creating a standard curve with six
cDNA dilutions (1:2–1:64). The Ct (Ct target gene – Ct
18S rRNA) for each dilution was plotted versus the log
amount of cDNA. The absolute value of the slope of these
graphs did not exceed 0.1 for any of the target genes, indi-
cating equal PCR efficiency. Relative expression was de-
termined by the Ct method as described by Livak and
Schmittgen.26 Ct for each gene (averaged across three an-
imals per group) was calculated relative to 18S rRNA (av-
eraged across three animals per group). Ct was then de-
termined as Ct (group 2) minus Ct (group 1), where group
1 is the carbohydrate control and group 2 is the cherry ex-
perimental group, and the values were then back-trans-
formed (2Ct) to calculate the relative abundance of each
transcript in the cherry-treated rats compared to untreated
carbohydrate control.
Hepatic neutral lipid analysis
Lipid was extracted from minced, frozen hepatic tissue
as described by Folch et al.27 Following extraction, total
cholesterol and triglyceride concentrations were measured
using commercially available colorimetric cholesterol and
triglyceride determination kits (Diagnostic Chemicals, Ox-
ford, CT) following the manufacturer’s instructions.
Hepatic FAS and ACO activity
All reagents used in the enzyme assays are pharmaceuti-
cal-grade from Sigma-Aldrich (St. Louis, MO). FAS enzyme
activity was determined using a modification of a previously
described assay.28 Briefly, frozen tissue was homogenized
on ice in 0.1 M potassium phosphate buffer (pH 7.0) con-
taining 8% sucrose, 1 mM EDTA (pH 8.0), and 20 mM 2-
mercaptoethanol. Tissue was sonicated using a 30-second
pulse of a Polytron (Brinkmann Instruments, Westbury, NY)
at maximum speed. Homogenates were then centrifuged at
3,000 g for 10 minutes at 4°C. For the FAS activity assay,
10 L of the supernatant was added to 80 L of assay buffer
(2 mM EDTA [pH 8.0], 2 mM dithiothreitol, and 0.4 mg/mL
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NADPH), and the rate of NADPH oxidation at 30°C was
monitored at 340 nm in a Pharmacia (Piscataway, NJ) Ul-
trospec 4300 Pro ultraviolet-visible spectrophotometer. One
unit of FAS activity was determined by subtracting the
NADPH oxidation rate from the rate after adding 10 L of
0.85 mg/mL malonyl-CoA, expressed as nanomoles of
NADPH oxidized per minute at 37°C per milligram of to-
tal protein in the sample. For the ACO activity assay, a per-
oxisome-rich fraction was prepared form the whole cell ho-
mogenate as reported by Small et al.29 ACO activity was
measured from the rate of palmitoyl-CoA-dependent H2O2
production coupled with dichlorofluorescein oxidation at
520 nm. One unit of activity was defined as 1 nmol of dichlo-
rofluorescein oxidized/minute at 30°C. Protein concentra-
tions were determined using a BCA Protein Assay kit
(Pierce, Rockford, IL).
Statistical methods
Differences in mRNA levels are shown as mean  SD,
as required by the Ct method as described by Livak and
Schmittgen.26 All other values are expressed mean  SEM.
Treatments were compared using a two-tailed Student’s t
test. A value of P  .05 was considered statistically signif-
icant.
RESULTS AND DISCUSSION
Figure 1 indicates that cherry-enriched diets had no sig-
nificant impact on body weight gain throughout the 90-day
study. As shown in Table 3, fasting glucose, total choles-
terol, triglyceride, and insulin are significantly reduced in
the tart cherry-fed animals. The cherry diet did not signifi-
cantly impact measures of liver function or other clinical
chemistries, although blood urea nitrogen and amylase were
reduced by cherry intake, perhaps suggesting improved re-
nal function and pancreatic function, respectively. Tart cher-
ries contain many phytochemicals with antioxidant poten-
tial, so we also tested diet effect on markers of oxidative
stress. Plasma antioxidant status was significantly improved
by tart cherry, while the effect on the lipid oxidation marker
8-isoprostane approached significance (P  .08). The cherry
diet was associated with a nonsignificant increase in heart,
liver, and kidney weight relative to total body weight as
compared to the control diet (Table 4).
Figure 2 shows that tart cherry diets significantly en-
hanced PPAR- (P  .05) transcript level, while PPAR-
mRNA approached significance (P  .08). Also, PPAR-
target ACO mRNA is strongly increased by the cherry-sup-
plemented diet, and Figure 3 shows that ACO activity is also
significantly enhanced. Hepatic PPAR- target FAS mRNA
was only moderately increased, and Figure 3 reveals a sim-
ilarly small effect on hepatic FAS activity. Because ACO
transcription is regulated by PPAR- and because greater
hepatic ACO activity reduces fat storage by promoting fat
oxidation, the effect of cherry diet on enhanced hepatic ACO
may explain the reduced hepatic triglyceride and cholesterol
content observed in Table 4. The effects on both PPAR-
and PPAR- correlate with moderately increased hepatic
weight (Table 4), despite significantly reduced hepatic
steatosis. These concurrent effects are also observed in rats
given PPAR agonist drugs, which causes proliferation of cel-
lular peroxisomes and increased organ weight.21–24
Possible PPAR-related mechanisms
The data relative to PPAR- and - isoforms presented
here are supported by previous findings with concentrated
anthocyanins or anthocyanin-rich botanical extracts.
Munoz-Espada and Watkins8 showed in prostate cancer cells
that exposure to cyanidin increases PPAR- expression. Xia
et al.9 showed in isolated macrophages that isolated antho-
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TABLE 3. SERUM AND PLASMA MEASURES
CHE CON
Total cholesterol (mg/dL) 75  4* 87  5
Total triglycerides (mg/dL) 28  3* 34  3
Glucose (mg/dL) 104  7* 119  8
Insulin (pg/mL) 6.2  0.5* 7.8  0.5
Albumin (mg/dL) 3.7  0.2 3.5  0.2
Alkalin phosphatase (U/L) 90  6 92  5
ALT (U/L) 61  4 66  4
AST (U/L) 187  12 183  9
Amylase (U/L) 1,502  13* 2,034  16
BUN (mg/dL) 18  1* 24  2
Creatinin (mg/dL) 0.5  0.1 0.5  0.1
Total protein (g/dL) 7  2 7  1
Plasma TAS (mmol/L) 0.94  0.05* 0.81  0.04
Plasma 8-isoprostane (pg/mL) 48  3 50  4
Data are mean  SEM values (n  12 per group). ALT, alanine
aminotransferase; AST, aspartate aminotransferase; BUN, blood urea
nitrogen; CHE, cherry-supplemented diet; CON, carbohydrate-
supplement control diet; TAS, total antioxidant status.
*P  .05 for comparison with CON value.
FIG. 1. Body weight change. Data are mean  SEM values (n 
12 animals per group).
cyanins induced cholesterol efflux in a PPAR--dependent
manner and that anthocyanins increased both PPAR- ex-
pression and PPAR- transcriptional activity in a dose-de-
pendent fashion. Park et al.6 showed in diabetic mice that
diets enriched with anthocyanin-rich mulberry leaf extract,
Korean red ginseng, and banaba leaf extract reduced glu-
cose, insulin, and triglyceride levels while increasing liver
and fat tissue expression of PPAR- and PPAR- and liver
lipoprotein lipase. It is compelling that the smaller dose of
anthocyanins in the tart cherry-enriched diets used here re-
tained biologic effects as compared to these earlier studies
with concentrated extracts. It is possible that synergy among
tart cherry phytochemicals or nutrients enhances antho-
cyanin bioavailability or efficacy.
In the current study, tart cherry-enriched diet was asso-
ciated with significantly increased hepatic PPAR- mRNA
expression. PPAR- is expressed largely in the liver and
skeletal muscle and controls multiple target genes that are
involved in lipid metabolism, including fatty acid oxidation
and fatty acid transport. As such, PPAR- agonist fibrate
drugs are generally effective in lowering elevated plasma
triglycerides and cholesterol. The effect of whole tart cher-
ries on reduced hyperlipidemia and hepatic steatosis may be
derived from one of more of these PPAR--related mecha-
nisms, such as the enhanced ACO expression observed here.
Tart cherry-enriched diets reduced fasting blood glucose
and fasting insulin, and these effects may be due to antho-
cyanin-mediated agonism of PPAR-. PPAR- is expressed
in fat, muscle, and liver. In these tissues, PPAR- regulates
genes important for adipogenesis, lipid metabolism, and glu-
cose control. As such, drugs that activate PPAR- like the
thiazolidinedione class have several effects that impact the
pathogenesis of insulin resistance and Type 2 diabetes.30–36
The current study was mainly focused on hepatic effects of
diet, and cherry diet-associated effects on hepatic PPAR-
mRNA approached significance. In the liver, PPAR- ago-
nist drugs up-regulate the expression of genes involved in
lipid uptake and lipid storage, like FAS.37 Because we ob-
served reduced rather than enhanced hepatic fat storage, the
lipid oxidation-promoting effects of PPAR- agonism ap-
pear to have overcome the effects of moderate PPAR- ag-
onism, but this assumption would need to be confirmed with
more broad assessments of PPAR-related transcripts.
Current study findings in context
The study presented here uses a whole food model to
test previous in vivo findings with concentrated, select an-
thocyanins or anthocyanin-rich botanical extracts. Tsuda
et al.38 showed that in high-fat-fed mice, an anthocyanin-
rich extract from purple corn significantly reduced fat
mass, hyperlipidemia, hyperinsulinemia, and blood glu-
cose. The anthocyanin extract-enriched diet also signifi-
cantly reduced tissue lipid accumulation and the activity
of enzymes that promote fat storage. Xia et al.5,39 showed
in atherosclerosis-prone mice that diets supplemented with
an anthocyanin-rich extract from black rice significantly
reduced atherosclerosis, total cholesterol, triglyceride, and
tissue cholesterol and increased high-density lipoprotein
(HDL). Finne-Nielsen et al.3 showed in rabbits that diets
supplemented with anthocyanin-containing black currant
juice significantly reduced VLDL and plasma total triglyc-
erides while not significantly reducing total cholesterol. In-
terestingly, in this study, diets supplemented with the pu-
rified anthocyanins instead of anthocyanin-rich black
currant juice increased cholesterol in a dose-dependent
manner. Therefore, it may be concluded that the whole
food provided the benefit rather than the isolated antho-
cyanins. Our findings in a whole food model reflect those
obtained with anthocyanin-rich botanical extracts, sug-
gesting that the anthocyanins in tart cherry may be the ac-
tive constituent towards these metabolic syndrome pheno-
types of interest. However, we cannot exclude the benefits
of other cherry-derived phytochemicals including quercetin,
melatonin, kaempferol, etc. These compounds may exert in-
dependent or synergistic effects towards our observed phe-
notypes.
Nair and colleagues recently conducted a study in mice
using Cornelian “cherry.”40 This is not a true cherry of
the agriculturally employed Prunus species, but is rather
the red fruit of an ornamental dogwood tree (Cornus mas).
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TABLE 4. ORGAN WEIGHTS AND LIVER NEUTRAL LIPID CONTENT
CHE CON
Heart weight/body weight (g/g  100) 3.7  0.2 3.2  0.5
Liver weight/body weight (g/g  100) 27.5  3 25.9  3
Kidney weight/body weight (g/g  100) 4.7  0.3 4.5  0.3
Hepatic cholesterol (mol/g) 29  4* 43  4
Hepatic triglyceride (mol/g) 143  11* 185  25
Data are mean  SEM values (n  12 per group). CHE, cherry-
supplemented diet; CON, carbohydrate-supplement control diet.
*P  .01 for comparison with CON value.
FIG. 2. Change in hepatic mRNA transcript levels in cherry-treated
rats compared to the control group. Data are mean  SD values (n 
3 per group). Threshold cycles of the transcripts in cherry-fed rat liv-
ers were internally normalized to the 18S gene (Ct) and compared
with control liver (Ct). *P  .05 versus CON value.
Jayaprakasam et al.40 reported that C57Bl/6 mice ingest-
ing Cornelian cherry-derived anthocyanin extract with a
high-fat diet showed a significant decrease in weight gain
and hepatic lipid accumulation while maintaining blood
glucose control. However, mice fed the anthocyanin-free,
high-fat diet gained weight and developed hyperglycemia,
indicating the importance of the anthocyanin content to
the treatment effect. The dose of Cornus anthocyanins
used (0.1% of diet by weight) is fivefold higher than the
total anthocyanins employed in the efficacious 1% tart
cherry diet (0.02% of diet by weight) presented here. It is
uncertain if a lower dose of Cornelian cherry anthocyanins
would have retained a treatment effect, or if the whole tart
cherry powder employed here provides a superior deliv-
ery mechanism for bioactive anthocyanins. For example,
the whole cherry fruit contains several antioxidant con-
stituents such as quercetin and melatonin that may stabi-
lize the various anthocyanins. Additionally, these cherry
phytochemicals may work synergistically in vivo with the
anthocyanins.
A recent well-designed clinical trial tested the health ef-
fects of sweet cherry (rather than tart cherry) consumption
in healthy men and women.41 Subjects consumed 45 pit-
ted Bing sweet cherries for 28 days, after which they were
examined for changes in low-density lipoprotein (LDL),
HDL, VLDL, insulin, and blood glucose. Plasma concen-
trations for total cholesterol, LDL-cholesterol, HDL-choles-
terol, triglyceride, and the total cholesterol:HDL-cholesterol
ratio were not influenced by cherry intake. The particle sizes
for VLDL, LDL, and HDL were similarly not affected by
cherry consumption. Fasting blood glucose concentrations
were also not affected, but insulin was slightly elevated by
sweet cherry intake.  There could be several explanations
for the different results between the current tart cherry study
and this human sweet cherry study. The human subjects were
healthy and did not display risk factors for metabolic syn-
drome; they had normal blood lipids, normal fasting glu-
cose, and normal fasting insulin. However, sweet cherry diet
effects on these parameters might only be observable in sub-
jects/animals with or at risk for metabolic syndrome, such
as the Dahl-SS rat. In addition, sweet cherries typically have
lower total anthocyanin levels than tart cherries. It is hy-
pothesized that the lower pH of the tart cherries stabilizes
and prolongs anthocyanin integrity. In addition, the 28-day
intervention with sweet cherry may not have been sufficient
to observe a treatment effect and/or limited by the small
number of test subjects (n  18).
Study limitations and future directions
Bioequivalency between rodents and humans is not
known because of species differences and differences in
metabolic rates. Therefore, dosage was calculated using a
conversion factor based upon the average difference in av-
erage adult human and adult rat body weight (250-fold dif-
ference). The IQF powder equivalent of 60 fresh cherries
equals 45 g because of loss of weight on drying, so the
rodent equivalent dose was calculated to be 45 g/250, or
200 mg of powder/day. Given the average AIN-76a ad li-
bitum intake of 20 g/day (determined in our preliminary
studies with the Dahl-SS rat42), 200 mg of cherry pow-
der/day represents 1% of the daily diet. Other methods of
bioequivalency determination may lead to different “dose”
estimations to test for relevance to human diets.
We did not include measures of PPAR- mRNA in other
tissues involved in insulin sensitivity/resistance like skele-
tal muscle36 or adipose tissue. We are currently pursuing
these end points, because the PPAR- isoform is more abun-
dant in these tissues than it is in the liver. Also, the tissue
distribution of PPAR isoforms in rats and humans is differ-
ent: the rat has relatively greater hepatic PPAR- expres-
sion, while human liver shows higher PPAR- expression.
As such, the tart cherry-associated effects observed here may
be more pronounced than would be observed in humans.
While our study revealed changes in total triglyceride and
total cholesterol, the altered lipoprotein fractions (HDL,
LDL, and VLDL) responsible for this change are not known.
In addition, while cholesterol-rich LDL is the prominent
lipoprotein in humans, HDL is the prominent lipoprotein in
rats. For clinical relevance, human or primate studies are
needed to identify cherry-mediated effects in specific
lipoprotein fractions.
In summary, tart cherry-enriched diets were associated
with significantly increased hepatic PPAR- expression, re-
duced hepatic lipid accumulation, reduced blood lipids, and
reduced fasting glucose and reduced hyperinsulinemia. In
addition, tart cherry diets were associated with increased ex-
pression and activity of a fat oxidizing enzyme, ACO, and
with enhanced plasma antioxidant capacity. As a rich whole-
food source of anthocyanins, tart cherry-enriched diets may
modify several key risk indicators for Type 2 diabetes. Fur-
ther studies are needed in human subjects with metabolic
syndrome to ascertain the degree and spectrum of tart
cherry-derived clinical benefits.
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FIG. 3. Hepatic ACO and FAS activity. Data are mean  SEM val-
ues, tested from a pooled homogenate from 12 rats in each group.
ACO activity is measured as nanomoles of dichlorofluorescein (DCF)
oxidized/minute/mg of protein, and FAS activity is measured as
nanomoles of NADPH oxidized/minute/mg of protein. Open bars are
cherry-supplemented rats, while black bars are control rats. *P  .05
versus control value.
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